摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

盐酸白毛莨碱 | 5936-28-7

中文名称
盐酸白毛莨碱
中文别名
(+)-B-金印草素盐酸盐
英文名称
(+)-β-hydrastine hydrochloride
英文别名
(-)-β-Hydrastine hydrochloride;β-hydrastine hydrochloride;(1S,9R)-(-)-β-Hydrastine;Hydrastine hydrochloride;(1R,9S)-β-hydrastine hydrochloride;(S)-6,7-dimethoxy-3-((R)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one; hydrochloride;(3S)-6,7-dimethoxy-3-[(5R)-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one;hydron;chloride
盐酸白毛莨碱化学式
CAS
5936-28-7
化学式
C21H21NO6*ClH
mdl
——
分子量
419.862
InChiKey
URBFHJWLYXILMP-VOMIJIAVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    115°C
  • 比旋光度:
    D17 +127° (c = 4 in dil HCl)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    29
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    66.5
  • 氢给体数:
    1
  • 氢受体数:
    7

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    Xn
  • 安全说明:
    S36
  • 危险类别码:
    R22
  • RTECS号:
    MU6125000
  • 包装等级:
    III
  • 危险类别:
    6.1(b)
  • 危险品运输编号:
    UN 1544

SDS

SDS:beb4dab16749d341c8514694df15b982
查看

反应信息

  • 作为反应物:
    描述:
    盐酸白毛莨碱氢氧化钾 作用下, 以 甲醇 为溶剂, 反应 90.0h, 生成 (±)-α-hydrastine
    参考文献:
    名称:
    Alkaloids of Corydalis incisa PERS. V. The structures of corydalispirone and corydalisol.
    摘要:
    从深切紫堇 PERS 中分离出两种新的生物碱,紫堇螺酮,C20H17O6N,熔点 196-198°,[α] D 0°,和紫堇醇,C20H21O5N,熔点 160-161°,[α] D +21.4°。 (罂粟科)。经光谱分析及与荷包牡丹二醇、阿杜脒二醇的化学关联,确定紫堇螺酮的结构为I,经转化为d-四氢黄连碱,确定紫堇醇的结构为VIII。紫堇螺酮和紫堇醇被认为是在苄基部分多一个碳原子的一系列新的异喹啉型生物碱,并且可能是黄连碱的代谢产物。
    DOI:
    10.1248/cpb.23.294
点击查看最新优质反应信息

文献信息

  • METHODS AND COMPOSITIONS FOR TREATING INFECTION
    申请人:UNIVERSITY OF ROCHESTER
    公开号:US20150238473A1
    公开(公告)日:2015-08-27
    Provided herein are compositions and methods for treating or preventing infection.
    本文提供了用于治疗或预防感染的组合物和方法。
  • Biotransformation of Phthalideisoquinoline Alkaloids by Corydalis Tissue Cultures
    作者:Kinuko Iwasa、Miyoko Kamigauchi、Narao Takao
    DOI:10.1002/ardp.19873200805
    日期:——
    The phthalideisoquinolines (−)‐α‐ and (−)‐β‐narcotine and (−)‐β‐hydrastine are metabolized to hydrocotarnine and hydrohydrastine, respectively, by Corydalis tissue cultures.
    邻苯二甲醚异喹啉 (-) - α- 和 (-) - β- 那可碱和 (-) - β- hydrastine 分别被紫堇属组织培养物代谢为氢化可硷宁和氢化胼胝碱。
  • Multi-Layer Tablets and Bioadhesive Dosage Forms
    申请人:Nangia Avinash
    公开号:US20080311191A1
    公开(公告)日:2008-12-18
    Bioadhesives coatings increase the gastrointestinal retention time of orally-ingested medicaments. Certain bioadhesive coatings producing a fracture strength of at least 100 N/m 2 , as measured on rat intestine, when applied to at least one surface of a pharmaceutical dosage form for oral delivery of a drug, result in a gastrointestinal retention time of at least 4 hours in a fed beagle dog model, during which the drug is released from the dosage form. Multi-layer tablets, particularly those including hydrophobic excipients, are useful in administering hygroscopic and/or deliquescent drugs. In addition, varying the amount of drug in multi-layer tablets allows the release rate of the drug to be controlled.
    生物粘合剂涂层可以增加口服药物的胃肠道保留时间。当应用于至少一种药物剂型的表面以口服给药时,产生至少100 N/m²的断裂强度的某些生物粘合剂涂层(在大鼠肠道上测量)可导致在饲养的比格犬模型中至少保留4小时的胃肠道保留时间,在此期间药物从剂型中释放。多层片剂,特别是包括疏水助剂的多层片剂,可用于给予吸湿性和/或易溶性药物。此外,改变多层片剂中药物的量可以控制药物的释放速率。
  • Methods and compositions for treating infection
    申请人:UNIVERSITY OF ROCHESTER
    公开号:US10004701B2
    公开(公告)日:2018-06-26
    Provided herein are compositions and methods for treating or preventing infection.
    本文提供了用于治疗或预防感染的组合物和方法。
  • Acceptably non-hygroscopic formulation intermediate comprising a hygroscopic drug
    申请人:——
    公开号:US20040197411A1
    公开(公告)日:2004-10-07
    A solid particulate composition is provided comprising a hygroscopic and/or deliquescent drug and at least one non-hygroscopic polymer. The drug and the at least one polymer are in intimate association and the composition is acceptably non-hygroscopic.
    一种固体颗粒组合物由吸湿性和/或潮解性药物和至少一种非吸湿性聚合物组成。药物和至少一种聚合物紧密结合,组合物具有可接受的非吸湿性。
查看更多

同类化合物

阿托喹啉 那可汀 那可丁N-氧化物 诺司卡品 盐酸盐 水合物 细果角茴香碱 紫堇明 盐酸那可丁一水合物 盐酸诺格考平 盐酸白毛莨碱 曲托喹啉 山缘草定碱 咖喏定 北美黄连碱 [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 [6S,(+)]-6-[(1S)-1,2,3,4-四氢-6,7-二甲氧基-2-甲基异喹啉-1-基]呋喃并[3,4-e]-1,3-苯并二氧戊环-8(6H)-酮 7-氨基-4,5,6-三乙氧基-3-(6,7,8-三甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基)-3H-2-苯并呋喃-1-酮 7-O-去甲基alpha-那可丁 6,7-二甲氧基-3-[(5R)-4-甲氧基-6-甲基-7,8-二氢-5H-[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-3H-2-苯并呋喃-1-酮 3-异喹啉-1-基-3H-2-苯并呋喃-1-酮 (3S)-6,7-二甲氧基-3-[(5S)-6-甲基-5,6,7,8-四氢[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-2-苯并呋喃-1(3H)-酮 (3S)-3-[(1R)-6,7-二羟基-8-甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基]-6,7-二甲氧基-3H-2-苯并呋喃-1-酮 (-)-荷苞牡丹碱甲溴化物 (-)-荷苞牡丹碱 (-)-荷包牡丹碱甲溴化物 (-)-荷包牡丹碱甲氯化物 (-)-紫堇明 (+)-荷苞牡丹碱甲氯化物 (+)-荷包牡丹碱 hydrastidine isohydrastidine 5,9-bis-(4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline (S,R)-9-bromo noscapine (S)-3-{(R)-9-[(2-chloro-acetylamino)-methyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-6,7-dimethoxy-phthalide (S)-6,7-dimethoxy-3-{(R)-4-methoxy-6-methyl-9-[(2-morpholino-acetylamino)-methyl]-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-phthalide (R)-5-((S)-4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline-9-carboxylic acid methyl ester 4-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid ethyl 4-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate N-(3-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)phenyl)acetamide (S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-7-hydroxy-6-methoxyisobenzofuran-1(3H)-one ethyl 2-chloro-5-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate 3-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)propane-1-sulfonic acid 4-(((S)-5-methoxy-1-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid (3S)-6,7-dimethoxy-3-((5R)-4-methoxy-6-methyl-9-(4-vinylphenyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one (R)-5-((S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline-9-carbaldehyde N-desmethyl-N-carbethoxynarcotine (S)-3-((R)-9-bromo-4-methoxy-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxyisobenzofuran-1(3H)-one 9-Fluoro-Noscapine 9-Nitro-Noscapine 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one